We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Gyre Therapeutics Inc (GYRE) USD0.001

Sell:$9.44 Buy:$15.53 Change: $0.56 (3.56%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$9.44
Buy:$15.53
Change: $0.56 (3.56%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$9.44
Buy:$15.53
Change: $0.56 (3.56%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.

Contact details

Address:
12770 High Bluff Drive, Suite 150
SAN DIEGO
92130
United States
Telephone:
+1 (619) 9493681
Website:
https://www.gyretx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GYRE
ISIN:
US4037831033
Market cap:
$1.19 billion
Shares in issue:
85.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Songjiang Ma
    President, Director
  • Han Ying
    Chief Executive Officer, Director
  • Ruoyu Chen
    Interim Chief Financial Officer
  • Weiguo Ye
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.